First Trust Advisors LP increased its stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Free Report) by 142.6% during the 3rd quarter, HoldingsChannel.com reports. The institutional investor owned 701,649 shares of the pharmaceutical company’s stock after buying an additional 412,470 shares during the quarter. First Trust Advisors LP’s holdings in Vertex Pharmaceuticals were worth $366,829,000 as of its most recent SEC filing.
A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. BNP Paribas raised its stake in Vertex Pharmaceuticals by 8.7% during the third quarter. BNP Paribas now owns 4,350 shares of the pharmaceutical company’s stock valued at $2,275,000 after buying an additional 348 shares during the last quarter. State Street Corp boosted its holdings in Vertex Pharmaceuticals by 1.3% in the third quarter. State Street Corp now owns 12,024,456 shares of the pharmaceutical company’s stock worth $6,286,506,000 after acquiring an additional 152,997 shares in the last quarter. Ilmarinen Mutual Pension Insurance Co boosted its holdings in Vertex Pharmaceuticals by 22.8% in the third quarter. Ilmarinen Mutual Pension Insurance Co now owns 41,500 shares of the pharmaceutical company’s stock worth $21,697,000 after acquiring an additional 7,700 shares in the last quarter. E Fund Management Hong Kong Co. Ltd. grew its stake in shares of Vertex Pharmaceuticals by 51.7% in the third quarter. E Fund Management Hong Kong Co. Ltd. now owns 2,250 shares of the pharmaceutical company’s stock worth $1,176,000 after acquiring an additional 767 shares during the last quarter. Finally, Rathbones Group PLC grew its stake in shares of Vertex Pharmaceuticals by 3.7% in the third quarter. Rathbones Group PLC now owns 1,083 shares of the pharmaceutical company’s stock worth $566,000 after acquiring an additional 39 shares during the last quarter. Institutional investors own 90.96% of the company’s stock.
Vertex Pharmaceuticals Stock Performance
VRTX stock opened at $514.75 on Friday. The stock has a market capitalization of $130.51 billion, a PE ratio of 33.12, a price-to-earnings-growth ratio of 2.73 and a beta of 0.28. Vertex Pharmaceuticals Incorporated has a 12-month low of $412.27 and a 12-month high of $568.67. The company has a current ratio of 2.34, a quick ratio of 1.89 and a debt-to-equity ratio of 0.17. The stock’s 50 day simple moving average is $522.72 and its 200 day simple moving average is $485.26.
Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report) last issued its earnings results on Monday, November 2nd. The pharmaceutical company reported $4.76 EPS for the quarter, missing the consensus estimate of $4.82 by ($0.06). The business had revenue of $3.44 billion for the quarter, compared to analysts’ expectations of $3.42 billion. Vertex Pharmaceuticals had a net margin of 30.70% and a return on equity of 21.98%. The business’s revenue for the quarter was up 11.8% on a year-over-year basis. During the same quarter in the prior year, the business posted $4.80 earnings per share. As a group, research analysts forecast that Vertex Pharmaceuticals Incorporated will post 16.10 earnings per share for the current fiscal year.
Analysts Set New Price Targets
VRTX has been the subject of several analyst reports. TD Cowen raised their price target on Vertex Pharmaceuticals from $550.00 to $575.00 and gave the company a “buy” rating in a report on Tuesday, November 3rd. Wells Fargo & Company upped their price target on shares of Vertex Pharmaceuticals from $550.00 to $650.00 and gave the stock an “overweight” rating in a research note on Tuesday, November 3rd. Rothschild & Co Redburn upped their price target on shares of Vertex Pharmaceuticals from $570.00 to $580.00 and gave the stock a “buy” rating in a research note on Wednesday, August 5th. Royal Bank Of Canada increased their price objective on shares of Vertex Pharmaceuticals from $576.00 to $600.00 and gave the company an “outperform” rating in a research report on Tuesday, November 3rd. Finally, Morgan Stanley reduced their price objective on shares of Vertex Pharmaceuticals from $665.00 to $660.00 and set an “overweight” rating for the company in a research note on Tuesday, November 3rd. One investment analyst has rated the stock with a Strong Buy rating, twenty-five have given a Buy rating and two have issued a Hold rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $596.44.
Check Out Our Latest Research Report on Vertex Pharmaceuticals
Insider Transactions at Vertex Pharmaceuticals
In other news, EVP Charles Wagner, Jr. sold 15,286 shares of the company’s stock in a transaction on Thursday, November 12th. The stock was sold at an average price of $547.87, for a total transaction of $8,374,740.82. Following the transaction, the executive vice president directly owned 31,764 shares of the company’s stock, valued at $17,402,542.68. This represents a 32.49% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Sangeeta N. Bhatia sold 271 shares of the stock in a transaction on Monday, November 16th. The shares were sold at an average price of $547.86, for a total value of $148,470.06. Following the sale, the director directly owned 4,653 shares in the company, valued at $2,549,192.58. This trade represents a 5.50% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 16,557 shares of company stock worth $9,071,071 over the last quarter. 0.20% of the stock is currently owned by insiders.
Vertex Pharmaceuticals Company Profile
Vertex Pharmaceuticals is a biotechnology company headquartered in Boston, Massachusetts. Founded in 1989, it develops medicines for serious diseases, with a long-standing focus on cystic fibrosis (CF). Vertex’s CF treatments include medicines that target the underlying protein defect, such as Trikafta/Kaftrio, Alyftrek, Kalydeco, Orkambi and Symdeko/Symkevi. The company also markets Journavx, a non-opioid medicine for acute pain, and partnered with CRISPR Therapeutics to develop Casgevy, a gene-editing treatment for sickle cell disease and transfusion-dependent beta thalassemia.
Read More
- Five stocks we like better than Vertex Pharmaceuticals
- ZIM Just Posted Huge Profits, But Its $35 Buyout Is Still in Limbo
- Owens Corning’s Stock Slump May Have a Silver Lining for Dividend Investors
- The Patchpocalypse Could Be a Big Opportunity for These 2 Cybersecurity Stocks
- Anthropic’s Record IPO Could Ease a Major Concern for Broadcom Investors
Want to see what other hedge funds are holding VRTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Free Report).
Receive News & Ratings for Vertex Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
